Oral oncology最新文献

{"title":"Dosimetric comparison of oral tongue dose with tongue-out radiation therapy compared to non-tongue-out radiation therapy for head & neck cancer: Clinical implications for mitigating post-radiation therapy dysgeusia","authors":"Whoon Jong Kil ,&nbsp;Wyatt Smith ,&nbsp;David Cousins","doi":"10.1016/j.oraloncology.2025.107335","DOIUrl":"10.1016/j.oraloncology.2025.107335","url":null,"abstract":"<div><div>Authors report oral tongue (OT)-sparing radiotherapy (RT) with tongue-out (TORT) for various virtual primary head and neck cancer (HNC). TORT lowered D_mean to OT by 25 % than non-TORT (22.4 <em>vs</em> 29.4 Gy, p &lt; 0.05); V₃₀ by 65 % (15.2 % <em>vs</em> 43.3 %, p &lt; 0.05) suggesting clinical implications for minimizing post-RT dysgeusia in HNC patients.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107335"},"PeriodicalIF":4.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral complications from treatment for human papilloma virus-positive oropharyngeal cancer","authors":"Alessandro Villa ,&nbsp;Stephen Sonis","doi":"10.1016/j.oraloncology.2025.107306","DOIUrl":"10.1016/j.oraloncology.2025.107306","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107306"},"PeriodicalIF":4.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of histopathologic assessment for head and neck oncologists","authors":"Amanda J. Bastien ,&nbsp;Daniel Manzoor ,&nbsp;Horacio Maluf ,&nbsp;Bonnie Balzer ,&nbsp;Matthew Leong ,&nbsp;Evan S. Walgama ,&nbsp;Kevin C. Scher ,&nbsp;Julie K. Jang ,&nbsp;Justin Moyers ,&nbsp;Jon Mallen-St. Clair ,&nbsp;Zachary S. Zumsteg ,&nbsp;Allen S. Ho","doi":"10.1016/j.oraloncology.2025.107286","DOIUrl":"10.1016/j.oraloncology.2025.107286","url":null,"abstract":"<div><h3>Goal of Review</h3><div>With a deeper understanding of histopathologic assessment, head and neck oncology specialists (surgical oncologists, radiation oncologists, and medical oncologists) will be better equipped to address the increasing complexity encompassing head and neck cancer management.</div></div><div><h3>Introduction</h3><div>Histopathologic assessment of surgical specimens imparts crucial information that is essential for post-operative treatment planning and prognostication for patients with head and neck squamous cell carcinoma (HNSCC). Herein, we discuss the most current guidelines and recommendations to elucidate the clinically relevant histopathologic features in HNSCC. This review discusses the following pathology features: extranodal extension, margins, perineural invasion, histologic grade, dysplasia, depth of invasion, lymphovascular invasion, and other considerations such as p16 immunohistochemistry, HPV in situ hybridization and worst pattern of invasion.</div></div><div><h3>Discussion</h3><div>Understanding histopathology in HNSCC is essential for accurate diagnosis, prognostication, understanding tumor behavior, and treatment management. This complexity of care has led to consensus guidelines from numerous authorities which this paper discusses and summarizes for readers.</div></div><div><h3>Conclusion</h3><div>The understanding of key histopathology elements in HNSCC will augment multidisciplinary discussions and improve patient care. The current variability in existing consensus guidelines highlights the need for improved standardization of histopathology reporting in HNSCC. Standardization will enhance diagnostic accuracy, guide clinical decision-making, and facilitate the development of more effective treatment strategies.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107286"},"PeriodicalIF":4.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conditional survival and dynamic failure hazard of oral cavity squamous cell carcinoma: Shedding light on the optimization of treatment and surveillance","authors":"Nuo Yu ,&nbsp;Yuchao Ma ,&nbsp;Lin Li ,&nbsp;Xin Guo ,&nbsp;Shiran Sun ,&nbsp;Yang Meng ,&nbsp;Xiaodong Huang ,&nbsp;Ye Zhang ,&nbsp;Runye Wu ,&nbsp;Kai Wang ,&nbsp;Xuesong Chen ,&nbsp;Yuan Qu ,&nbsp;Jianghu Zhang ,&nbsp;Qingfeng Liu ,&nbsp;Jingwei Luo ,&nbsp;Jianping Xiao ,&nbsp;Ye-Xiong Li ,&nbsp;Jingbo Wang ,&nbsp;Junlin Yi","doi":"10.1016/j.oraloncology.2025.107294","DOIUrl":"10.1016/j.oraloncology.2025.107294","url":null,"abstract":"<div><h3>Purpose</h3><div>To provide a comprehensive analysis of conditional survival (CS) and dynamic failure hazards in oral cavity squamous cell carcinoma (OCSCC), enhancing prognostic understanding and facilitating more individualized treatment strategy and surveillance.</div></div><div><h3>Method</h3><div>Patients with non-metastatic OCSCC undergoing surgery between 1999 and 2018 were retrospectively analyzed. Overall survival (OS), disease-free survival (DFS), conditional OS (COS), and conditional DFS (CDFS) were calculated. Annual hazards, including death, progression, and stage-specific risks, were estimated using Kernel-based methods.</div></div><div><h3>Results</h3><div>Among 700 patients (median follow-up: 97.6 months), the 5-year OS and DFS were 68.3 % and 62.0 %, respectively. The 5-year COS improved from 71 % after one year to 86 % after five years, while the 5-year CDFS increased from 76 % to 87 %. Annual hazard rates for death and progression peaked in the first two years post-surgery, with death hazard declining from 9.8 % to 3.3 % and progression hazard decreasing from 20.0 % to 2.9 % by the fifth year. Stage-specific death hazards peaked at varying timings: the second year for stages I/II, the third year for stage III, and the first two years for stage IV. Progression hazards peaked in the first year for all stages, with stage IV showing the highest risk at 32.0 %, decreasing to ∼ 4 % by the fourth year.</div></div><div><h3>Conclusion</h3><div>This study provides an updated overview of CS and dynamic failure hazards in OCSCC, particularly emphasizing the high progression hazard in stage IV patients during the first year. These findings support tailored treatment strategies and rigorous early surveillance to improve outcomes.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107294"},"PeriodicalIF":4.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing the scope and impact of photobiomodulation research in head and neck cancer therapy","authors":"Carlos M. Ardila","doi":"10.1016/j.oraloncology.2025.107303","DOIUrl":"10.1016/j.oraloncology.2025.107303","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107303"},"PeriodicalIF":4.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143870899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on, “Molecular features of T and N stage progression in laryngeal cancer.”","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.oraloncology.2025.107331","DOIUrl":"10.1016/j.oraloncology.2025.107331","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107331"},"PeriodicalIF":4.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143856073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tongue tumor and prognostic factors: Could a diagnostic procedure influence patient outcomes?","authors":"Marta Tagliabue ,&nbsp;Rita De Berardinis ,&nbsp;Giulia Doi ,&nbsp;Francesco Chu ,&nbsp;Jessica Mellia ,&nbsp;Alberto Luchena ,&nbsp;Fausto Maffini ,&nbsp;Roberto Bruschini ,&nbsp;Stefano Zorzi ,&nbsp;Gioacchino Giugliano ,&nbsp;Stefano Riccio ,&nbsp;Sara Gandini ,&nbsp;Susanna Chiocca ,&nbsp;Mohssen Ansarin","doi":"10.1016/j.oraloncology.2025.107298","DOIUrl":"10.1016/j.oraloncology.2025.107298","url":null,"abstract":"<div><h3>Objectives</h3><div>Diagnosis of tongue tumors is often performed in primary care centers with an incisional biopsy using stitches in the lesion at the end of the procedure. We hypothesize that stitches placed in tumor tissue could potentially increase local inflammation and significantly affect the tumor microenvironment, influencing the cancer spread and local relapses.</div></div><div><h3>Materials and methods</h3><div>We conducted a retrospective study involving a consecutive series of 299 patients with Oral Tongue Squamous Cell Carcinoma (OTSCC). The study population was divided into two groups: Group 1 consisting of patients who did not receive stitches during the biopsy and, Group 2 composed by patients who had stitches placed in the tumor at the time of diagnosis. All data collected were statistically analyzed.</div></div><div><h3>Results</h3><div>The use of stitches during biopsy was associated with a negative prognostic role in Disease Free Survival (DFS), Disease Specific Survival (DSS) and a worsening trend in cause specific overall survival (cs-OS) for early stages (I-II) OTSCC. This negative prognostic impact was confirmed in the cumulative multivariable analyses of the DFS and DSS curves for stages I-II. The negative prognostic impact was not observed for patients with advanced-stage carcinoma and for OS.</div></div><div><h3>Conclusion</h3><div>Our analysis suggested that the placement of stitches during biopsy in patients with early OTSCC may worsen outcomes in terms of DFS and DSS. We recommend evaluating whether stitches are truly necessary during biopsy or if they could be avoided altogether by using less invasive biopsy techniques.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107298"},"PeriodicalIF":4.0,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143859333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes following IMRT alone in head and neck squamous cell carcinoma ordinarily managed with concurrent chemo-radiotherapy","authors":"Marc Vincent N. Barcelona ,&nbsp;John Waldron ,&nbsp;Brian O’ Sullivan ,&nbsp;Jie Su ,&nbsp;Scott V. Bratman ,&nbsp;John Byoung Cho ,&nbsp;Ezra Hahn ,&nbsp;Andrew J. Hope ,&nbsp;Ali Hosni ,&nbsp;John Kim ,&nbsp;Andrew McPartlin ,&nbsp;Jolie Ringash ,&nbsp;Nauman Malik ,&nbsp;Lillian L. Siu ,&nbsp;Anna Spreafico ,&nbsp;Lawson Eng ,&nbsp;Enrique Sanz-Garcia ,&nbsp;Christopher Michael Kai-Lup Yao ,&nbsp;John de Almeida ,&nbsp;Li Tong ,&nbsp;Shao Hui Huang","doi":"10.1016/j.oraloncology.2025.107299","DOIUrl":"10.1016/j.oraloncology.2025.107299","url":null,"abstract":"<div><h3>Purpose/Objective(S)</h3><div>We report outcomes following IMRT-alone in patients with head-and-neck squamous cell carcinoma (HNSCC) ordinarily managed with concurrent chemo-radiotherapy.</div></div><div><h3>Materials/Methods</h3><div>HNSCC (excluding T1-2 N0) patients treated with IMRT-alone from 2005 to 2019 were included and restaged according to TNM-8. Overall survival (OS) was stratified by TNM-8 stage subgroups within HPV-positive (HPV + ) and separately within HPV-negative (HPV–) HNSCC. Multivariable analysis (MVA) identified prognostic factors for OS.</div></div><div><h3>Results</h3><div>A total of 460 patients with HPV + and 623 HPV– HNSCC were identified. Reasons for chemotherapy omission were: age &gt; 70 years and/or frailty (n = 551, 51 %), cisplatin contraindication (n = 241, 22 %), patient’ preference (n = 106, 10 %), and clinician’s decision (n = 185, 17 %). IMRT was delivered mostly using altered-fractionation: moderately-accelerated (70 Gy/35 fractions [f]/6 weeks [w], 55 %), hypofractionated (60 Gy/25f/5w, 14 %), and hyperfractionated-accelerated (64 Gy/40f/4w, 25 %). Median follow-up was 5.0 years. Five-year OS for HPV + stage-I-single node, stage-I-multiple nodes, stage-II-T1-2 N2, stage-II-T3 N0-N2, and stage-III were 90 %, 79 %%, 80 %, 64 %, and 33 %, and for HPV– stage III, IVA, and IVB were 47 %, 27 %, and 13 %, respectively. MVA confirmed lower OS in HPV + stage-I-multiple nodes (p = 0.03), II-T3 N0-N2 and III (vs stage-I-single node) and HPV– stage IVA/IVB (vs III) (p &lt; 0.01), and marginally lower OS in HPV + stage-II-T3 N0-2 (vs I-single node) (p = 0.07).</div></div><div><h3>Conclusion</h3><div>Altered fractionated IMRT-alone is a valid option for patients with HPV + stage I-single node HNSCC, and an acceptable alternative for elderly/frail or cisplatin ineligible patients with HPV + stage I-multiple nodes and T1-2 N2 HNSCC. Patients with HPV + T3-T4 or N3 and HPV– stage III/IV HNSCC had unsatisfactory OS, requiring further research into alternative options.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107299"},"PeriodicalIF":4.0,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143851779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on, “Factors associated with detection of oligometastatic recurrence and outcome following definitive (chemo)radiotherapy for oropharyngeal carcinoma.”","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.oraloncology.2025.107332","DOIUrl":"10.1016/j.oraloncology.2025.107332","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107332"},"PeriodicalIF":4.0,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143856062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment outcomes of sinonasal adenoid cystic carcinoma: a single-center experience","authors":"Hye-Bin Jang,&nbsp;Dong Hoon Lee,&nbsp;Sang Chul Lim","doi":"10.1016/j.oraloncology.2025.107317","DOIUrl":"10.1016/j.oraloncology.2025.107317","url":null,"abstract":"<div><h3>Objective</h3><div>Sinonasal adenoid cystic carcinoma (ACC) is a rare malignancy characterized by perineural invasion and a high risk of late recurrence. This study examines the clinical characteristics and treatment outcomes of patients with sinonasal ACC treated at a single institution over 15 years.</div></div><div><h3>Patients and methods</h3><div>A retrospective analysis was conducted on 19 patients with histologically confirmed sinonasal ACC treated at Chonnam National University Hwasun Hospital from 2010 to 2024.</div></div><div><h3>Results</h3><div>Nasal obstruction was the most common presenting symptom (57.8 %), followed by facial pain and numbness (21.0 %) and epistaxis (10.5 %). The maxillary sinus was the most frequently affected site (52.6 %). At initial diagnosis, regional lymph node and distant metastases were each observed in one patient. Most cases were diagnosed at stage IV (57.9 %), with perineural invasion detected in 31.6 % of cases. Among the 17 patients who completed treatment, surgery followed by radiotherapy was the predominant treatment modality (82.4 %). Two patients were deemed inoperable and received definitive chemoradiotherapy or best supportive care. Over a mean follow-up of 87.5 ± 60.2 months, 11 patients (64.7 %) experienced recurrence, with a mean time to recurrence of 52.8 ± 45.7 months. Survival analysis identified tumor stage as the only significant prognostic factor (<em>p</em> &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>Sinonasal ACC is frequently diagnosed at an advanced stage and demonstrates a high recurrence rate despite multimodal treatment. The tumor stage emerged as the strongest prognostic indicator of survival, highlighting the need for early detection and aggressive therapeutic interventions to improve patient outcomes.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"165 ","pages":"Article 107317"},"PeriodicalIF":4.0,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143850067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}